Inoveon Corporation Terry L. Crabtree President and Chief Executive Officer 800 Research Parkway Suite 370 Oklahoma City, OK 73104 Phone: 405/271-9025 FAX: 405/271-9026 www.inoveon.com *Inoveon’s Diabetic Retinopathy Digital Disease Detection and Tracking Service (DR 3DT TM) has converted world class research protocols into the highest value, convenient, diagnostic test available to provide "gold standard" evaluations for staging diabetic retinopathy, the leading cause of blindness in working aged Americans. *Diabetic retinopathy is a leading cause of blindness worldwide and causes many more patients with diabetes debilitating moderate vision loss. With consistent periodic retinal evaluations early stages of high risk disease can be detected, effectively managed and treated with laser surgery. *The American Academy of Ophthalmology, and the American Diabetes Association have published guidelines recommending annual retinal evaluations for patients with diabetes to better manage and effectively treat diabetic retinopathy. Although the guidelines are well publicized, the patient compliance for receiving this annual exam is often not followed. *Oklahoma City based Inoveon Corporation has integrated all the components necessary to provide the best method of evaluating diabetic retinopathy. By developing The Digital Disease Detection and Tracking service (3DT‘) a digital imaging system, deployed via distributed networks, leveraging Internet communications, with comprehensive workflow and quality assurance protocols, this "gold standard" service can now be made available to the vast population of patients with diabetes in the primary care environment. *The Inoveon 3 DT service brings retinal evaluations closer to the patient population in settings where they get most of their routine care encouraging a greater compliance with guidelines. Increased compliance greatly increases the number of diabetics evaluated each year resulting in early detection of diabetic retinopathy and appropriate treatment for the elimination of blindness and loss of sight. *Providing this service to patients in the primary care setting enables their primary physicians to stay involved in the management of the entire disease state, resulting in greater patient convenience, better outcomes and lower costs.